UNASSIGNED: Cell culture and animal work indicate that @entity5735 ( @entity5735 ) inhibition may exert cardiovascular benefits through favorable effects on the vascular endothelium. Prior @entity1 studies evaluating @entity5735 inhibition have shown conflicting results that may in part be related to heterogeneity of background anti- @entity6 therapies. No study has evaluated the acute response of the vasculature to @entity5735 inhibition in @entity1 . We recruited 38 @entity1 with @entity164 2 @entity6 on stable background @entity2449 therapy for a randomized, double-blind, placebo-controlled crossover trial of @entity5735 inhibition with @entity12350 (100 mg/day). Each treatment period was 8 weeks long separated by 4 weeks of washout. Endothelial function and plasma markers of endothelial activation ( @entity2071 ( @entity2071 ) and @entity4725 ( @entity4725 )) were measured prior to and 2 hours following acute dosing of @entity12350 or placebo, as well as following 8 weeks of intervention with each pill. Thirty subjects completed the study and were included in analyses. Neither acute nor chronic @entity12350 therapy resulted in significant changes in vascular endothelial function. While post-acute @entity12350 @entity2071 levels were lower than that post-chronic @entity12350 , the @entity2071 concentration was not significantly different than pre-acute @entity12350 levels or levels measured in relationship to placebo. There were no significant changes in plasma @entity4725 levels at any time point. Acute and chronic @entity12350 therapies have neutral effects on the vascular endothelium in the setting of @entity2449 background therapy. In conclusion, our findings suggest @entity5735 inhibition has a neutral effect on cardiovascular risk in @entity1 without a history of @entity712 or @entity177 . TRIAL REGISTRATION: NCT01859793.

Impact of @entity5735 inhibition on acute and chronic endothelial function in XXXX with @entity164 2 @entity6 on background @entity2449 therapy.

@entity1 :: ('9606', 'Species') :: ['humans', 'human', 'patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity5735 :: ('1803', 'Gene') :: ['dipeptidyl peptidase-4', 'DPP-4'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity4725 :: ('7412', 'Gene') :: ['vascular cell adhesion molecule 1', 'VCAM-1'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule 1'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity1 :: (9606,Species) :: ['humans']
